Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

RNAC

Cartesian Therapeutics Inc

Dec 13 • 04:00PM ET

18.68

Dollar change -1.44
Percentage change -7.13	%

Healthcare • Biotechnology • USA • NASD

Peers: ALNY IONS SRPT ARWR PBYI BLUE CRSP EDIT GILD VRTX

| Held by: IWM VTI IWO VXF VTWO IWC VTWG RSSL JFWD UWM

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-52.64	Insider Own	59.92%	Shs Outstand	23.90M	Perf Week	-25.68%
Market Cap	441.01M	Forward P/E	-	EPS next Y	-3.39	Insider Trans	2.78%	Shs Float	10.19M	Perf Month	9.14%
Income	-286.59M	PEG	-	EPS next Q	-0.81	Inst Own	22.36%	Short Float	17.96%	Perf Quarter	16.71%
Sales	47.94M	P/S	9.20	EPS this Y	89.72%	Inst Trans	116.04%	Short Ratio	15.71	Perf Half Y	-31.53%
Book/sh	0.03	P/B	593.74	EPS next Y	33.83%	ROA	-102.11%	Short Interest	1.83M	Perf Year	-11.38%
Cash/sh	9.29	P/C	2.01	EPS next 5Y	-	ROE	-938.38%	52W Range	11.66 - 41.87	Perf YTD	-9.66%
Dividend Est.	-	P/FCF	-	EPS past 5Y	10.69%	ROI	-2268.56%	52W High	-55.37%	Beta	0.54
Dividend TTM	-	Quick Ratio	10.70	Sales past 5Y	230.86%	Gross Margin	98.05%	52W Low	60.18%	ATR (14)	2.33
Dividend Ex-Date	-	Current Ratio	10.70	EPS Y/Y TTM	-645.78%	Oper. Margin	-109.96%	RSI (14)	44.51	Volatility	16.29% 11.87%
Employees	38	Debt/Eq	19.53	Sales Y/Y TTM	38.82%	Profit Margin	-597.83%	Recom	1.57	Target Price	37.40
Option/Short	No / Yes	LT Debt/Eq	15.84	EPS Q/Q	35.44%	Payout	-	Rel Volume	0.70	Prev Close	20.12
Sales Surprise	-69.04%	EPS Surprise	-40.95%	Sales Q/Q	-94.09%	Earnings	Nov 07 BMO	Avg Volume	116.51K	Price	18.68
SMA20	-6.30%	SMA50	-9.42%	SMA200	-6.23%	Trades		Volume	82,105	Change	-7.13%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-06-24	Initiated	TD Cowen	Buy
Jul-02-24	Downgrade	Oppenheimer	Outperform → Perform
Jun-04-24	Initiated	Oppenheimer	Outperform	$50
May-24-24	Initiated	Mizuho	Buy	$40
Apr-23-24	Reiterated	H.C. Wainwright	Buy	$2 → $54
Apr-23-24	Initiated	Leerink Partners	Outperform	$39
Aug-18-23	Downgrade	SVB Securities	Outperform → Market Perform	$1
Jun-14-22	Reiterated	Needham	Buy	$6 → $5
Jun-06-22	Initiated	SVB Leerink	Outperform	$7
Jun-15-21	Initiated	BTIG Research	Buy	$10
Jan-26-21	Upgrade	Mizuho	Neutral → Buy	$2.50 → $8
Oct-01-20	Downgrade	William Blair	Outperform → Mkt Perform
Oct-01-20	Downgrade	Mizuho	Buy → Neutral	$2.50
Jun-12-20	Downgrade	Stifel	Buy → Hold
Apr-28-20	Initiated	H.C. Wainwright	Buy	$8
Jan-29-20	Initiated	Cantor Fitzgerald	Overweight	$10
Jan-21-20	Initiated	William Blair	Outperform
Jun-27-18	Initiated	Janney	Buy	$33
Mar-30-17	Reiterated	UBS	Buy	$26

Show Previous Ratings

Dec-04-24 06:33AM	Cartesian Therapeutics Reports Promising Phase 2b Trial Results (TipRanks) +9.56%
Dec-03-24 06:00AM	Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial (GlobeNewswire)
Nov-21-24 07:00AM	Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit (GlobeNewswire)
Nov-14-24 10:01AM	Yale University's Strategic Bet on Cartesian Therapeutics Skyrockets in Q3 2024 (GuruFocus.com)
Nov-08-24 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
07:00AM	Loading…
Nov-07-24 07:00AM	Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-05-24 09:00AM	Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting (GlobeNewswire)
Oct-15-24 07:00AM	Cartesian Therapeutics Announces Presentation of Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2024 MGFA Scientific Session of the AANEM Annual Meeting (GlobeNewswire) -5.58%
Oct-04-24 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire) +7.45%
Sep-09-24 07:00AM	Cartesian Therapeutics Receives FDA Rare Pediatric Disease Designation for Descartes-08 for the Treatment of Juvenile Dermatomyositis (GlobeNewswire)
Sep-06-24 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grant (GlobeNewswire) -7.55%
Sep-03-24 07:00AM	Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15 (GlobeNewswire) -6.02%
Aug-26-24 07:00AM	Cartesian Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-08-24 07:00AM	Cartesian Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire) -9.43%
Aug-07-24 04:05PM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
04:05PM	Loading…
Jul-08-24 04:05PM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
Jul-03-24 02:25PM	Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates (Zacks) +11.73%
Jul-02-24 04:08PM	Cartesian Therapeutics Plummets Despite 'Watershed Moment' For CAR-T Drugs (Investor's Business Daily) -35.02%
04:05PM	Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik (GlobeNewswire)
06:31AM	Cartesian Therapeutics Announces First Patient Dosed in Phase 2 Trial of Descartes-08 in Systematic Lupus Erythematosus (GlobeNewswire)
06:31AM	Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing (GlobeNewswire)
06:30AM	Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis (GlobeNewswire)
Jun-06-24 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grant (GlobeNewswire)
May-23-24 12:12PM	Cartesian (RNAC) Up as FDA Grants RMAT Tag to Descartes-08 (Zacks)
May-22-24 07:00AM	Cartesian Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Descartes-08 for the Treatment of Myasthenia Gravis (GlobeNewswire)
May-13-24 04:30PM	Cartesian Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire) +15.38%
12:00PM	What Makes Cartesian Therapeutics, Inc. (RNAC) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Think Cartesian Therapeutics, Inc. (RNAC) Could Surge 141%: Read This Before Placing a Bet (Zacks)
May-10-24 03:12PM	Cartesian Therapeutics Inc (RNAC) Reports Q1 2024 Earnings: A Detailed Financial and ... (GuruFocus.com)
May-08-24 02:52PM	RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:00AM	Loading…
07:00AM	Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-06-24 04:15PM	Cartesian Therapeutics Announces New Employment Inducement Grants (Business Wire) -9.85%
Apr-25-24 09:55AM	Wall Street Analysts Believe Cartesian Therapeutics, Inc. (RNAC) Could Rally 146.24%: Here's is How to Trade (Zacks)
Apr-22-24 04:30PM	Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting (Business Wire) +12.76%
Apr-08-24 09:35AM	Down -30.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Cartesian Therapeutics, Inc. (RNAC) (Zacks)
Apr-04-24 07:30AM	Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
07:00AM	Cartesian Therapeutics Announces New Employment Inducement Grants (Business Wire)
Apr-02-24 05:41PM	Insiders Are Buying These 11 Penny Stocks (Insider Monkey) -5.36% -7.55%
Mar-28-24 04:05PM	Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split (GlobeNewswire) -13.83%
Mar-14-24 09:35AM	Cartesian Therapeutics, Inc. (RNAC) Loses -24.65% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Mar-07-24 11:51PM	RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -8.04%
07:00AM	Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-06-24 07:00AM	Cartesian Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-05-24 07:05AM	Cartesian Therapeutics Announces New Employment Inducement Grant (GlobeNewswire)
07:00AM	Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland (GlobeNewswire)
Feb-05-24 04:05PM	Cartesian Therapeutics Announces New Employment Inducement Grants (GlobeNewswire) -9.18% +5.35%
Jan-22-24 09:19AM	Why Is Cartesian Therapeutics (RNAC) Stock Down 5% Today? (InvestorPlace)
Jan-08-24 07:10AM	Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity (GlobeNewswire) +5.87%
07:00AM	Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis (GlobeNewswire)
Nov-13-23 08:05AM	Selecta Biosciences Announces Merger with Cartesian Therapeutics (GlobeNewswire) -8.00%
Oct-31-23 04:03PM	Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi (GlobeNewswire) -7.20%
Aug-24-23 06:21AM	The Petri Dish: Selecta gets selective with drug programs; Moderna enters 2nd cancer vaccine collab (American City Business Journals)
Aug-17-23 10:20PM	Q2 2023 Selecta Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
08:15AM	Selecta Biosciences, Inc. (SELB) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics (GlobeNewswire)
Jul-14-23 07:08AM	Selecta Biosciences, Inc.'s (NASDAQ:SELB) largest shareholders are individual investors with 35% ownership, institutions own 26% (Simply Wall St.)
Jul-13-23 03:00PM	10 Best Revenue Growth Stocks to Buy (Insider Monkey)
Jun-03-23 08:20AM	Selecta Biosciences (NASDAQ:SELB) shareholders are up 22% this past week, but still in the red over the last five years (Simply Wall St.)
May-31-23 07:00AM	Selecta Biosciences Announces Presentation of Data from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout During Late-Breaking Session at the EULAR 2023 European Congress of Rheumatology (GlobeNewswire)
May-09-23 06:06AM	Newsflash: Selecta Biosciences, Inc. (NASDAQ:SELB) Analysts Have Been Trimming Their Revenue Forecasts (Simply Wall St.)
May-04-23 08:45AM	Selecta Biosciences, Inc. (SELB) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -6.96%
07:30AM	Selecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Apr-28-23 04:05PM	Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2023 Financial Results and Provide Business Update (GlobeNewswire) -5.04%
Apr-18-23 06:11AM	Investors Holding Back On Selecta Biosciences, Inc. (NASDAQ:SELB) (Simply Wall St.)
Mar-27-23 07:07AM	Is Selecta Biosciences, Inc.'s (NASDAQ:SELB) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? (Simply Wall St.) -5.67%
Mar-21-23 11:48AM	Selecta, SOBI's Chronic Refractory Gout Program Meets Primary Goal, US Submission Expected Next Year (Benzinga)
03:30AM	Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout Meets Primary Endpoint (GlobeNewswire)
Mar-06-23 05:59AM	Selecta Biosciences, Inc. (NASDAQ:SELB) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-03-23 01:24AM	Q4 2022 Selecta Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-02-23 09:25AM	Selecta Biosciences, Inc. (SELB) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Selecta Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Feb-23-23 08:00AM	Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Update (GlobeNewswire)
Feb-07-23 01:51PM	The 7 Best Biotech Stocks to Buy for February 2023 (InvestorPlace)
08:00AM	Selecta Biosciences to Participate at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-31-23 01:15PM	Analyst Says Selecta Biosciences' Gout Candidate Can Potentially Raise The Bar On Several Fronts (Benzinga)
Jan-17-23 11:33AM	Positive week for Selecta Biosciences, Inc. (NASDAQ:SELB) institutional investors who lost 34% over the past year (Simply Wall St.)
Jan-12-23 05:39AM	The Petri Dish: Moderna looks at new price tag for Covid vaccine (American City Business Journals) +5.44%
Jan-09-23 08:00AM	Selecta Biosciences Provides Business Update and Outlook for 2023 (GlobeNewswire) +8.13%
07:30AM	Selecta Biosciences and Astellas Announce Exclusive Licensing and Development Agreement for Xork IgG Protease (PR Newswire)
Dec-21-22 10:29AM	Shareholders in Selecta Biosciences (NASDAQ:SELB) have lost 89%, as stock drops 19% this past week (Simply Wall St.)
Dec-14-22 08:00AM	Selecta Biosciences Announces Next Generation IgA Protease Clinical Candidate Selection for IgA Nephropathy Program (GlobeNewswire)
Dec-01-22 05:43AM	The Petri Dish: bluebird gets $102M; BMS vet joins Selecta's C-suite (American City Business Journals)
Nov-28-22 08:00AM	Selecta Biosciences Announces Appointment of Blaine Davis as Chief Financial Officer (GlobeNewswire)
Nov-09-22 06:36AM	Selecta Biosciences Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.) -8.39%
Nov-07-22 08:00AM	Selecta Biosciences to Participate at the Guggenheim Healthcare Talks \| 4th Annual Immunology & Neurology Day (GlobeNewswire)
Nov-03-22 09:15AM	Selecta Biosciences, Inc. (SELB) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Selecta Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Oct-27-22 08:00AM	Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Business Update (GlobeNewswire)
Oct-18-22 06:13AM	Could The Market Be Wrong About Selecta Biosciences, Inc. (NASDAQ:SELB) Given Its Attractive Financial Prospects? (Simply Wall St.)
Oct-11-22 08:00AM	Selecta Biosciences Announces Three Presentations at the Upcoming 29th Annual European Society of Gene and Cell Therapy (ESGCT) Conference (GlobeNewswire) +7.89%
Oct-10-22 06:10PM	Elevance Health's (ELV) Low-Cost MA Plans to Widen U.S. Base (Zacks) -7.88%
Sep-29-22 08:00AM	Selecta Biosciences Board Member, Timothy Springer, Ph.D., Wins Lasker Award for Seminal Discovery of Key Adhesion Molecules that Mediate Immune Cell Interactions (GlobeNewswire) -5.29%
Sep-12-22 08:00AM	Selecta Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Sep-06-22 08:00AM	Selecta Biosciences to Participate at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-30-22 06:21AM	Selecta Biosciences (NASDAQ:SELB) Has A Pretty Healthy Balance Sheet (Simply Wall St.)
Aug-29-22 05:08PM	This Small-Cap Biotech is a Sneaky Play on Next-Gen Drugs (TheStreet.com)
Aug-12-22 09:30AM	10 Best One Dollar Stocks To Buy Now (Insider Monkey)
Aug-09-22 10:25AM	Need To Know: Analysts Are Much More Bullish On Selecta Biosciences, Inc. (NASDAQ:SELB) (Simply Wall St.)
Aug-06-22 08:25AM	What Kind Of Investors Own Most Of Selecta Biosciences, Inc. (NASDAQ:SELB)? (Simply Wall St.)
Aug-04-22 09:05AM	Selecta Biosciences, Inc. (SELB) Q2 Earnings and Revenues Surpass Estimates (Zacks) +13.94%

Cartesian Therapeutics, Inc. operates as a clinical-stage biotechnology company. It provides mRNA cell therapies for the treatment of autoimmune diseases. It operates in research and development of cell therapy product candidates. The company is headquartered in Gaithersburg, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kurtoglu Metin	Chief Technology Officer	Dec 09 '24	Option Exercise	1.41	10,763	15,176	61,796	Dec 11 04:28 PM
Kurtoglu Metin	Chief Technology Officer	Dec 10 '24	Option Exercise	1.41	2,901	4,090	53,934	Dec 11 04:28 PM
Kurtoglu Metin	Chief Technology Officer	Dec 09 '24	Sale	25.50	10,763	274,494	51,033	Dec 11 04:28 PM
Kurtoglu Metin	Chief Technology Officer	Dec 10 '24	Sale	24.35	2,901	70,640	51,033	Dec 11 04:28 PM
METIN KURTOGLU	Officer	Dec 10 '24	Proposed Sale	24.35	2,901	70,640		Dec 10 04:21 PM
METIN KURTOGLU	Officer	Dec 09 '24	Proposed Sale	25.50	10,763	274,493		Dec 09 04:36 PM
Kurtoglu Metin	Chief Technology Officer	Nov 21 '24	Option Exercise	1.41	32,789	46,232	83,822	Nov 21 06:52 PM
Kurtoglu Metin	Chief Technology Officer	Nov 20 '24	Option Exercise	1.41	5,700	8,037	56,733	Nov 21 06:52 PM
Kurtoglu Metin	Chief Technology Officer	Nov 19 '24	Option Exercise	1.41	200	282	51,233	Nov 21 06:52 PM
Kurtoglu Metin	Chief Technology Officer	Nov 21 '24	Sale	16.67	32,789	546,560	51,033	Nov 21 06:52 PM
Kurtoglu Metin	Chief Technology Officer	Nov 20 '24	Sale	17.29	5,700	98,570	51,033	Nov 21 06:52 PM
Kurtoglu Metin	Chief Technology Officer	Nov 19 '24	Sale	19.50	200	3,900	51,033	Nov 21 06:52 PM
Jewell Christopher M	Chief Scientific Officer	Nov 20 '24	Option Exercise	3.23	14,000	45,220	39,940	Nov 21 06:50 PM
METIN KURTOGLU	Officer	Nov 21 '24	Proposed Sale	16.67	32,789	546,560		Nov 21 04:45 PM
METIN KURTOGLU	Officer	Nov 20 '24	Proposed Sale	17.29	5,700	98,570		Nov 20 04:57 PM
METIN KURTOGLU	Officer	Nov 19 '24	Proposed Sale	19.50	200	3,900		Nov 19 04:36 PM
SPRINGER TIMOTHY A	Director	Nov 15 '24	Buy	17.09	277,246	4,739,188	8,397,411	Nov 18 07:35 PM
SPRINGER TIMOTHY A	Director	Nov 14 '24	Buy	16.37	96,399	1,578,156	8,120,165	Nov 18 07:35 PM
SPRINGER TIMOTHY A	Director	Nov 18 '24	Buy	18.12	58,295	1,056,183	8,455,706	Nov 18 07:35 PM
Kurtoglu Metin	Chief Technology Officer	Nov 18 '24	Option Exercise	1.41	34,400	48,504	85,433	Nov 18 07:32 PM
Kurtoglu Metin	Chief Technology Officer	Nov 14 '24	Option Exercise	1.41	25,900	36,519	76,933	Nov 18 07:32 PM
Kurtoglu Metin	Chief Technology Officer	Nov 15 '24	Option Exercise	1.41	22,068	31,116	73,101	Nov 18 07:32 PM
Kurtoglu Metin	Chief Technology Officer	Nov 18 '24	Sale	18.39	34,400	632,641	51,033	Nov 18 07:32 PM
Kurtoglu Metin	Chief Technology Officer	Nov 14 '24	Sale	16.44	25,900	425,900	51,033	Nov 18 07:32 PM
Kurtoglu Metin	Chief Technology Officer	Nov 15 '24	Sale	17.20	22,068	379,497	51,033	Nov 18 07:32 PM
Miljkovic Milos	Chief Medical Officer	Nov 14 '24	Option Exercise	3.23	35,000	113,050	53,273	Nov 18 07:28 PM
Miljkovic Milos	Chief Medical Officer	Nov 15 '24	Option Exercise	3.23	20,000	64,600	38,273	Nov 18 07:28 PM
Miljkovic Milos	Chief Medical Officer	Nov 14 '24	Sale	16.13	35,000	564,644	18,273	Nov 18 07:28 PM
Miljkovic Milos	Chief Medical Officer	Nov 15 '24	Sale	17.14	20,000	342,888	18,273	Nov 18 07:28 PM
Jewell Christopher M	Chief Scientific Officer	Nov 14 '24	Option Exercise	3.23	36,050	116,442	61,990	Nov 18 07:23 PM
Jewell Christopher M	Chief Scientific Officer	Nov 15 '24	Option Exercise	3.23	16,065	51,890	42,005	Nov 18 07:23 PM
Jewell Christopher M	Chief Scientific Officer	Nov 14 '24	Sale	16.67	36,050	600,949	25,940	Nov 18 07:23 PM
Jewell Christopher M	Chief Scientific Officer	Nov 15 '24	Sale	17.06	16,065	274,093	25,940	Nov 18 07:23 PM
METIN KURTOGLU	Officer	Nov 18 '24	Proposed Sale	18.39	34,400	632,640		Nov 18 04:24 PM
METIN KURTOGLU	Officer	Nov 15 '24	Proposed Sale	17.20	22,068	379,497		Nov 15 05:07 PM
CHRISTOPHER M JEWELL	Officer	Nov 15 '24	Proposed Sale	17.06	16,065	274,093		Nov 15 04:57 PM
MILOS MILJKOVIC	Officer	Nov 15 '24	Proposed Sale	17.14	20,000	342,889		Nov 15 04:44 PM
METIN KURTOGLU	Officer	Nov 14 '24	Proposed Sale	16.44	25,900	425,900		Nov 14 05:30 PM
CHRISTOPHER M JEWELL	Officer	Nov 14 '24	Proposed Sale	16.67	36,050	600,949		Nov 14 05:29 PM
MILOS MILJKOVIC	Officer	Nov 14 '24	Proposed Sale	16.13	35,000	564,644		Nov 14 05:13 PM
SPRINGER TIMOTHY A	Director	Oct 03 '24	Buy	19.89	119,906	2,384,713	7,943,465	Oct 04 05:58 PM
SPRINGER TIMOTHY A	Director	Oct 04 '24	Buy	22.58	80,301	1,813,010	8,023,766	Oct 04 05:58 PM
SPRINGER TIMOTHY A	Director	Oct 02 '24	Buy	17.38	5,514	95,822	7,823,559	Oct 04 05:58 PM
SPRINGER TIMOTHY A	Director	Aug 12 '24	Buy	12.72	8,016	101,968	11,509	Aug 14 04:43 PM
BARABE TIMOTHY C	Director	Aug 12 '24	Buy	12.70	7,500	95,250	21,766	Aug 14 04:41 PM
SPRINGER TIMOTHY A	Director	Mar 08 '24	Buy	0.66	4,800	3,187	95,218	Mar 28 05:11 PM
SPRINGER TIMOTHY A	Director	Mar 13 '24	Buy	0.58	3,200	1,868	100,818	Mar 28 05:11 PM
SPRINGER TIMOTHY A	Director	Feb 07 '24	Buy	0.66	2,400	1,575	90,418	Mar 28 05:11 PM
SPRINGER TIMOTHY A	Director	Mar 14 '24	Buy	0.53	2,000	1,061	102,818	Mar 28 05:11 PM
SPRINGER TIMOTHY A	Director	Mar 11 '24	Buy	0.65	1,200	785	96,418	Mar 28 05:11 PM
SPRINGER TIMOTHY A	Director	Mar 12 '24	Buy	0.61	1,200	735	97,618	Mar 28 05:11 PM
SPRINGER TIMOTHY A	Director	Mar 15 '24	Buy	0.56	1,200	672	104,018	Mar 28 05:11 PM
SPRINGER TIMOTHY A	Director	Jan 17 '24	Buy	0.69	800	552	87,218	Mar 28 05:11 PM
SPRINGER TIMOTHY A	Director	Feb 06 '24	Buy	0.65	800	520	88,018	Mar 28 05:11 PM
SPRINGER TIMOTHY A	Director	Mar 18 '24	Buy	0.61	800	488	104,818	Mar 28 05:11 PM
SPRINGER TIMOTHY A	Director	Mar 26 '24	Option Exercise	1.46	1,970,443	2,876,847	33,043,849	Mar 26 04:32 PM
SPRINGER TIMOTHY A	Director	Mar 18 '24	Buy	0.60	19,044	11,398	31,073,406	Mar 20 05:09 PM
SPRINGER TIMOTHY A	Director	Mar 14 '24	Buy	0.54	648,372	351,677	30,516,862	Mar 18 05:29 PM
SPRINGER TIMOTHY A	Director	Mar 15 '24	Buy	0.59	537,500	314,545	31,054,362	Mar 18 05:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RNAC

Cartesian Therapeutics Inc

Upgrade your FINVIZ experience